# US 2026/0092062 A1 · Pyridine carboxamide compounds and their use in treating medical conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092062 A1
- Document ID: US20260092062A1
- Status: Published application
- Kind: A1
- Application number: 19/113,556
- Filed: 2023-09-26
- Published: 2026-04-02
- Earliest claimed: 2022-09-26
- Assignees: Rectify Pharmaceuticals, Inc.
- Applicants: Rectify Pharmaceuticals, Inc.
- Inventors: Todd Bosanac; Nathan Oliver Fuller; Robert Owen Hughes; Guy Bemis; Janeta Valentina Popovici Muller
- Web page: https://patentgrep.com/patent/US20260092062A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 471/04: Ortho-condensed systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.

## Claims

### Claim 1

A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof; wherein:
Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl;
R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
R3 is hydrogen, cyclopropyl, or C1-3 alkyl optionally substituted with a group selected from —OH, OMe, —NH2, —NH(CH3), and —N(CH3)2;
R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R represents independently for each occurrence hydrogen, hydroxyl, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
n is 0, 1, 2, or 3; and
p is 0, 1, 2, 3 or 4.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula I.

### Claim 3 (depends on 1, 2)

The compound of either of claim 1 or 2, wherein Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Ring A is a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or phenyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R1 is —H, —CH3, —CH2C(O)NH2, —CH2OCH3, —CH2CH2OCH3, —NHAc, —OH, —C(O)CH2OH, —C(O)CH3, —CH2C(O)NH2, —OCH3, CH2OCH3, —C(O)OCH3, —C(O)OH, —NHCH2CH2OH, —CH2CH2C(O)OCH3, —NHS(O)2CH3, —C(O)NH2, —S(O)2CH3, Bn, —OC(CH3)2, —NHCH2CH2OCH3, —F, —Cl, —Br, (O), —CH2NH2, —NH2, —NHC(O)CH3, —C(O)OCH2CH3, —O-cyclopentyl, —S(O)2NHCH2CH2OH, —CH2CH3, —N(CH3)2, —CH(CH3)2, —CF3, —CN, —S(O)2CH3, —CH2OH, —OCH3, —CH2N(CH3)2, —CH2NHCH2CH2OH, —O(CH2)3N(CH3)2, —C(O)NH2, cyclohexyl, cyclopropyl, —OCF, —S(O)2NH2, —CHF2, —CH2NHC(O)OC(CH3)3, —C(CH3)2(OH), —CH(OH)CH3, or —O(CH2)2NR2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R2 is hydrogen.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R2 is C1-3 alkyl.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R2 is methyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R2 is cyclopropyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein R3 is hydrogen.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein R3 is C1-3 alkyl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein R3 is cyclopropyl.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein R3 is C1-3 alkyl substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the substitution on C1-3 alkyl occurs on the C1-3 alkyl terminal carbon atom.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R2 is methyl and R3 is hydrogen.

### Claim 17 (depends on 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-3 or 6-16, wherein the compound is of Formula I-A, I-B, or I-C:
or a pharmaceutically acceptable salt thereof, wherein:
X is nitrogen or carbon.

### Claim 18 (depends on 17)

The compound of claim 17, wherein X is nitrogen.

### Claim 19 (depends on 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-4 or 6-16, wherein the compound is of Formula I-D:
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R1 is —CH3, R2 is —CH3, and R3 is —H.

### Claim 21

A compound represented by Formula II:
or a pharmaceutically acceptable salt thereof; wherein:
Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl;
R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, or C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
R3 is hydrogen, cyclopropyl, or C1-3 alkyl optionally substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2;
R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
L1 is a bond, —OCH2—, —O—, —OCH2CH2—, —NHCH2—, —NHCH2CH2—, or —NH—;
Y represents independently for each occurrence —R, oxo, —OR, —NR2, —OCH2CHF2, —OCH2CH2OH, or —NHCH2CH2OR; or two Y groups attached to the same carbon atom can together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R represents independently for each occurrence —H, —OH, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
n is 0, 1, 2, or 3;
p is 0, 1, 2, 3 or 4; and
q is 0, 1 or 2.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the compound is a compound of Formula II.

### Claim 23 (depends on 21, 22)

The compound of either of claim 21 or claim 22, wherein Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 24 (depends on 21, 22, 23)

The compound of any one of claims 21-23, wherein Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 25 (depends on 21, 22, 23)

The compound of any one of claims 21-23, wherein Ring A is a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl.

### Claim 26 (depends on 21, 22, 23, 24, 25)

The compound of any one of claims 21-25, wherein R1 is —H, —CH3, —CH2C(O)NH2, —CH2OCH3, —CH2CH2OCH3, —NHAc, —OH, —C(O)CH2OH, —C(O)CH3, —CH2C(O)NH2, —OCH3, CH2OCH3, —C(O)OCH3, —C(O)OH, —NHCH2CH2OH, —CH2CH2C(O)OCH3, —NHS(O)2CH3, —C(O)NH2, —S(O)2CH3, Bn, —OC(CH3)2, —NHCH2CH2OCH3, —F, —Cl, —Br, (O), —CH2NH2, —NH2, —NHC(O)CH3, —C(O)OCH2CH3, —O-cyclopentyl, —S(O)2NHCH2CH2OH, —CH2CH3, —N(CH3)2, —CH(CH3)2, —CF3, —CN, —S(O)2CH3, —CH2OH, —OCH3, —CH2N(CH3)2, —CH2NHCH2CH2OH —O(CH2)3N(CH3)2, —C(O)NH2, cyclohexyl, cyclopropyl, —OCF3, —S(O)2NH2, —CHF2, —CH2NHC(O)OC(CH3)3, —C(CH3)2(OH), —CH(OH)CH3, or —O(CH2)2NR2.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The compound of any one of claims 21-26, wherein R2 is hydrogen.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26)

The compound of any one of claims 21-26, wherein R2 is C1-3 alkyl.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26)

The compound of any one of claims 21-26, wherein R2 is methyl.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26)

The compound of any one of claims 21-26, wherein R2 is cyclopropyl.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 21-30, wherein R3 is hydrogen.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 21-30, wherein R3 is C1-3 alkyl.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 21-30, wherein R3 is cyclopropyl.

### Claim 34 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 21-30, wherein R3 is C1-3 alkyl substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2.

### Claim 35 (depends on 34)

The compound of claim 34, wherein the substitution on C1-3 alkyl occurs on the C1-3 alkyl terminal carbon atom.

### Claim 36 (depends on 21, 22, 23, 24, 25, 26)

The compound of any one of claims 21-26, wherein R2 is methyl and R3 is hydrogen.

### Claim 37 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 21-36, wherein L1 is a bond, —O—, or —NH—.

### Claim 38 (depends on 37)

The compound of claim 37, wherein L1 is a bond.

### Claim 39

A compound represented by Formula III:
or a pharmaceutically acceptable salt thereof; wherein:
Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl;
R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, or C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
R3 is hydrogen, cyclopropyl, or C1-3 alkyl optionally substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2;
R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
X is —O— or —NH—;
R represents independently for each occurrence —H, —OH, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
n is 0, 1, 2, or 3; and
p is 0, 1, 2, 3 or 4.

### Claim 40 (depends on 39)

The compound of claim 39, wherein the compound is a compound of Formula III.

### Claim 41 (depends on 39, 40)

The compound of either of claim 39 or claim 40, wherein Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 42 (depends on 39, 40, 41)

The compound of any one of claims 39-41, wherein Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 43 (depends on 39, 40, 41)

The compound of any one of claims 39-41, wherein Ring A is a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The compound of any one of claims 39-43, wherein R1 is —H, —CH3, —CH2C(O)NH2, —CH2OCH3, —CH2CH2OCH3, —NHAc, —OH, —C(O)CH2OH, —C(O)CH3, —CH2C(O)NH2, —OCH3, CH2OCH3, —C(O)OCH3, —C(O)OH, —NHCH2CH2OH, —CH2CH2C(O)OCH3, —NHS(O)2CH3, —C(O)NH2, —S(O)2CH3, Bn, —OC(CH3)2, —NHCH2CH2OCH3, —F, —Cl, —Br, (O), —CH2NH2, —CH2NHCH2CH2OH, —NH2, —NHC(O)CH3, —C(O)OCH2CH3, —O-cyclopentyl, —S(O)2NHCH2CH2OH, —CH2CH3, —N(CH3)2, —CH(CH3)2, —CF3, —CN, —S(O)2CH3, —CH2OH, —OCH3, —CH2N(CH3)2, —O(CH2)3N(CH3)2, —C(O)NH2, cyclohexyl, cyclopropyl, —OCF3, —S(O)2NH2, —CHF2, —CH2NHC(O)OC(CH3)3, —C(CH3)2(OH), —CH(OH)CH3, or —O(CH2)2NR2.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

The compound of any one of claims 39-44, wherein R2 is hydrogen.

### Claim 46 (depends on 39, 40, 41, 42, 43, 44)

The compound of any one of claims 39-44, wherein R2 is C1-3 alkyl.

### Claim 47 (depends on 39, 40, 41, 42, 43, 44)

The compound of any one of claims 39-44, wherein R2 is methyl.

### Claim 48 (depends on 39, 40, 41, 42, 43, 44)

The compound of any one of claims 39-44, wherein R2 is cyclopropyl.

### Claim 49 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 39-48, wherein R3 is hydrogen.

### Claim 50 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 39-48, wherein R3 is C1-3 alkyl.

### Claim 51 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 39-48, wherein R3 is cyclopropyl.

### Claim 52 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 39-48, wherein R3 is C1-3 alkyl substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2.

### Claim 53 (depends on 52)

The compound of claim 52, wherein the substitution on C1-3 alkyl occurs on the C1-3 alkyl terminal carbon atom.

### Claim 54 (depends on 39, 40, 41, 42, 43, 44)

The compound of any one of claims 39-44, wherein R2 is methyl and R3 is hydrogen.

### Claim 55 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 39-54, wherein X is —O—.

### Claim 56 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 39-54, wherein X is —NH—.

### Claim 57

A compound represented by Formula IV:
or a pharmaceutically acceptable salt thereof; wherein:
R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —CH2NHCH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, or C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
R3 is hydrogen, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2;
R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R represents independently for each occurrence —H, —OH, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
n is 0, 1, or 2; and
p is 0, 1, 2, 3 or 4.

### Claim 58 (depends on 57)

The compound of claim 57, wherein the compound is a compound of Formula IV.

### Claim 59 (depends on 57, 58)

The compound of either of claim 57 or claim 58, wherein R1 is —H, —CH3, —CH2C(O)NH2, —CH2OCH3, —CH2CH2OCH3, —NHAc, —OH, —C(O)CH2OH, —C(O)CH3, —CH2C(O)NH2, —OCH3, CH2OCH3, —C(O)OCH3, —C(O)OH, —NHCH2CH2OH, —CH2CH2C(O)OCH3, —NHS(O)2CH3, —C(O)NH2, —S(O)2CH3, Bn, —OC(CH3)2, —NHCH2CH2OCH3, —F, —Cl, —Br, (O), —CH2NH2, —NH2, —NHC(O)CH3, —C(O)OCH2CH3, —O— cyclopentyl, —S(O)2NHCH2CH2OH, —CH2CH3, —N(CH3)2, —CH2NHCH2CH2OH, —CH(CH3)2, —CF3, —CN, —S(O)2CH3, —CH2OH, —OCH3, —CH2N(CH3)2, —O(CH2)3N(CH3)2, —C(O)NH2, cyclohexyl, cyclopropyl, —OCF3, —S(O)2NH2, —CHF2, —CH2NHC(O)OC(CH3)3, —C(CH3)2(OH), —CH(OH)CH3, or —O(CH2)2NR2.

### Claim 60 (depends on 57, 58, 59)

The compound of any one of claims 57-59, wherein R2 is hydrogen.

### Claim 61 (depends on 57, 58, 59)

The compound of any one of claims 57-59, wherein R2 is C1-3 alkyl.

### Claim 62 (depends on 57, 58, 59)

The compound of any one of claims 57-59, wherein R2 is methyl.

### Claim 63 (depends on 57, 58, 59)

The compound of any one of claims 57-59, wherein R2 is cyclopropyl.

### Claim 64 (depends on 57, 58, 59, 60, 61, 62, 63)

The compound of any one of claims 57-63, wherein R3 is hydrogen.

### Claim 65 (depends on 57, 58, 59, 60, 61, 62, 63)

The compound of any one of claims 57-63, wherein R3 is C1-3 alkyl.

### Claim 66 (depends on 57, 58, 59, 60, 61, 62, 63)

The compound of any one of claims 57-63, wherein R3 is cyclopropyl.

### Claim 67 (depends on 57, 58, 59, 60, 61, 62, 63)

The compound of any one of claims 57-63, wherein R3 is C1-3 alkyl substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2.

### Claim 68 (depends on 67)

The compound of claim 67, wherein the substitution on C1-3 alkyl occurs on the C1-3 alkyl terminal carbon atom.

### Claim 69 (depends on 57, 58, 59)

The compound of any of one of claims 57-59, wherein R2 is methyl and R3 is hydrogen.

### Claim 70

A compound in Table 1 herein, or a pharmaceutically acceptable salt thereof.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A pharmaceutical composition comprising a compound of any one of claims 1-70 and a pharmaceutically acceptable carrier.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A method of treating a disorder associated with ABC transporter dysfunction, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-70.

### Claim 73 (depends on 72)

The method of claim 72, wherein the disorder associated with ABC transporter dysfunction is characterized by dysfunction in a transporter selected from one or more of ABCA1, ABCA2, ABCA3, ABCA4, ABCA5, ABCA7, ABCA12, ABCB2, ABCB3, ABCB4, ABCB6, ABCB7, ABCB10, ABCB11, ABCC1, ABCC2, ABCC4, ABCC5, ABCC6, ABCC7, ABCC8, ABCC9, ABCC12, ABCD1, ABCD2, ABCD3, ABCD4, ABCG5, ABCG8, ABCG1, and ABCG4.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A method of treating a disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-70, wherein the disorder is selected from Tangier disease, Surfactant metabolism dysfunction pulmonary 3, autosomal recessive Ichthyosis congenital 4A (ARCI), Bare lymphocyte syndrome type I, Bare lymphocyte syndrome type I due to TAP2 deficiency, Dyschromatosis universalis hereditaria 3, X-linked sideroblastic anemia with ataxia, Dubin-Johnson Syndrome, Cystic fibrosis (CF), Familial Hyperinsulinemic Hypoglycemia 1, Intellectual disability Myopathy Syndrome, Congenital bile acid synthesis defect 5, Methylmalonic aciduria and homocystinuria cblJ type, Sitostrolemia, Stargardt disease, PFIC3, PFIC2, Pseudoxanthoma Elasticum, X-linked adrenoleukodystrophy (ALD), Cholestasis, Hyperbilirubinemia, Intrahepatic cholestasis of pregnancy, Biliary atresia, Alagille syndrome, primary biliary cholangitis, primary sclerosing cholangitis, NAFLD/NASH, Alzheimer's disease, Huntington's disease, Multiple sclerosis, Parkinson's disease, Hirschsprung disease, Zellweger syndrome, Type 2 diabetes, Obesity, Type 1 diabetes, Atherosclerosis, Dyslipidemia, Generalized arterial calcification of infancy, Calciphylaxis, Autosomal recessive cone-rod dystrophy, Gout, PFIC1, Myo5B deficiency cholestasis, PFIC4, and Low phospholipid associated cholelithiasis.

### Claim 75 (depends on 74)

The method of claim 74, wherein the disorder is Cystic fibrosis.

### Claim 76 (depends on 72, 73, 74, 75)

The method of any one of claims 72-75, wherein the subject is a human.
